XTX Topco’s POMDOCTOR LIMITED Class A Ordinary Shares POM Stock Holding History

XTX Topco’s Portfolio POM Stock Details POM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,413	Closed	-$48.1K	–	4895
2026 Q1	$48.1K	Sell	10,413 -10,107	-49%	-$51.8K	﹤0.01%	3331
2025 Q4	$109K	Buy	+20,520	New	+$1.34M	﹤0.01%	2613

Other funds holding POM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

XTX Topco's POM Position: Q2 2026 in Review

XTX Topco sold out of POMDOCTOR LIMITED Class A Ordinary Shares (POM) in Q2 2026, closing a stake of 10,413 shares — an estimated $48.1K sold.

XTX Topco first reported a position in POM in Q4 2025 and held it in 2 quarters. The position peaked at $109K in Q4 2025. 6 funds tracked by Wall St. Rank hold POM as of Q2 2026.

XTX Topco reported no remaining POMDOCTOR LIMITED Class A Ordinary Shares position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 10,413 POMDOCTOR LIMITED Class A Ordinary Shares shares in Q2 2026, an estimated $48.1K.
XTX Topco first reported a position in POMDOCTOR LIMITED Class A Ordinary Shares in Q4 2025 and held it in 2 quarters.
XTX Topco's POMDOCTOR LIMITED Class A Ordinary Shares position peaked at $109K in Q4 2025.
6 funds tracked by Wall St. Rank held POMDOCTOR LIMITED Class A Ordinary Shares as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.